GlassScriptPhysician profile
Hilary A Young
NPI 1013379601
$6,849.13
in general payments reported to CMS, 2019-2025
13 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,359 · 2022: $1,555 · 2023: $1,441 · 2024: $1,350 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370 · Consulting Fee: $500 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,369.96 |
| Consulting Fee | $500.00 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,092.11 | 2021-2025 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $1,080.36 | 2021-2025 | |
| Tg Therapeutics, INC. | $1,044.34 | 2022-2025 | |
| Banner Life Sciences, LLC | $988.34 | 2021-2022 | |
| Genzyme Corporation | $424.28 | 2022-2025 | |
| Emd Serono, INC. | $369.55 | 2022-2024 | Mavenclad |
| Genentech, INC. | $293.29 | 2022-2025 | Ocrevus |
| Celgene Corporation | $186.94 | 2022-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $181.54 | 2021-2022 | |
| Genentech USA, INC. | $69.55 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Alexion Pharmaceuticals, INC. | $44.89 | 2021 | |
| Vanda Pharmaceuticals INC. | $38.89 | 2025 | Ponvory |
| E.R. Squibb & Sons, L.L.C. | $35.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilary Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.